Clinical Topics & News
News
TNFSF13B variant linked to MS and SLE
A variant in the TNFSF13B gene has been linked to susceptibility to both multiple sclerosis and systemic lupus erythematosus, according to a...
News
Ocrelizumab gets first-ever FDA approval for primary progressive MS
The humanized monoclonal antibody ocrelizumab became the first drug to receive approval from the Food and Drug Administration for the treatment of...
Literature Review
Early Interferon Treatment Delays Time to Clinically Definite MS
In patients presenting with a first clinical demyelinating event, early treatment with subcutaneous interferon beta-1a three times per week over...
Literature Review
Switch From Fingolimod to Alemtuzumab Might Trigger MS Relapse
Nine patients with relapsing multiple sclerosis had significant and unexpected disease activity within 12 months of switching from fingolimod to...
Literature Review
Relatives of Patients With MS Show Early Signs of Disease
Asymptomatic first-degree relatives of patients with multiple sclerosis (MS) who are at high risk for developing the disease are significantly...
Literature Review
Treatment Reduces Risk of Long-Term Disability in MS
Compared with the natural history of the disease, disease-modifying treatments for multiple sclerosis (MS) significantly reduce the risks of long-...
Article
New report highlights gaps in knowledge on marijuana use
Evidence review shows when using cannabis or cannabinoids is effective, ineffective, or harmful.
Article
Switch from fingolimod to alemtuzumab might trigger MS relapse
Nine relapsing multiple sclerosis patients had significant and unexpected disease activity within 12 months of switching from fingolimod to...
Article
High-risk relatives of MS patients show early signs of disease
Asymptomatic first-degree relatives of multiple sclerosis patients at high risk for developing the disease were significantly more likely to show...
Article
Lack of natalizumab concentration increase before PML argues against extending dosing interval
Serum concentrations of natalizumab do not appear to rise before patients with relapsing-remitting multiple sclerosis are diagnosed with...